Status:
COMPLETED
PPI Test in GP Patients
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
UMC Utrecht
Conditions:
GERD
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the diagnostic value of two week treatment with Nexium as a confirmatory test for patients with suspected reflux disease.
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Symptoms suggestive for gastric acid reflux disease during 2 or more days per week
Exclusion
- Treatment with prokinetic or acid secretion inhibitors within 4 weeks prior to inclusion
- Treatment with a PPI for more than 30 days within the last 3 months prior to inclusion
- History of proven peptic ulcer disease, unless successfully treated with Helicobacter pylori eradication longer than 1 month before inclusion
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00318084
Start Date
January 1 2003
Last Update
August 17 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Utrecht, Netherlands